Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10184
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Hiroshima University
• Principal Investigator: Murakami Yoshiaki 広島大学, 医歯薬保健学研究科(医), 准教授 (10263683)
• Co-Investigator(Kenkyū-buntansha): 橋本 泰司 広島大学, 学内共同利用施設等, その他 (50423380) ; 上村 健一郎 広島大学, 医歯薬保健学研究科(医), 講師 (60379873)
• Research Collaborator: HADANO Naoto 広島大学, 大学院生
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 膵癌 / バイオマーカー / K-ras変異 / cell free DNA

Outline of Final Research Achievements

We used droplet digital polymerase chain reaction to detect rare mutant tumour-derived KRAS genes in plasma cell-free DNA (cfDNA) as ctDNA. Samples were collected from 105 patients who underwent pancreatoduodenectomy for PDAC at a single institution. Overall survival (OS) was analysed according to the presence of ctDNA.Among the 105 cases, ctDNA was detected in 33 (31%) plasma samples. The median OS durations were 13.6 months for patients with ctDNA (ctDNA+) and 27.6 months for patients without ctDNA. Patients who were ctDNA+ had a significantly poorer prognosis with respect to OS (P<0.0001).Our findings suggested that the presence of ctDNA in plasma samples could be an important and powerful predictor of poor survival in patients with PDAC. Accordingly, ctDNA detection might be a promising approach with respect to PDAC treatment.

Free Research Field

膵癌　バイオマーカー